Device deal making is back in a big way, despite the munificence of venture funds.
Shareholders are rewarding the kinds of companies they punished a year ago.
And consolidation in the diagnostics space is only just beginning.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.